OPZELURA 15 mg/g, cream tube, 100 g, CIP 3400930270981
Active ingredients: Ruxolitinib phosphate, Ruxolitinib
Commercialized according to BDPMDispensing in France: Prescription only
Creamtube, 100 g, CIP 3400930270981cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- OPZELURA 15 mg/g, crème
- Pharmaceutical form
- crème
- Route of administration
- cutanée
- Presentation description
- 1 tube(s) aluminium de 100 g
- Marketing authorisation holder
- INCYTE BIOSCIENCES DISTRIBUTION (PAYS-BAS)
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 31 Jan 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68279528CIP73027098CIP133400930270981Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| PHOSPHATE DE RUXOLITINIBcrème | — | SA |
| RUXOLITINIBcrème | 15 mg · 1 g de crème | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.